person
Przemysław R.
- Country
- Poland
- Department
- VITA LONGA Sp. z o.o
Research Overview
assignment
34
Clinical Trials ·
- A randomized, double-blind, placebo controlled, dose finding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis
- Safety Evaluation of SOR102 in Healthy Subjects and Ulcerative Colitis Patients: A Phase I Clinical Trial
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
329
Sites with multiple studies
Has run more than one trial at 329 of 544 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in studying advanced therapeutic approaches for inflammatory bowel disease (IBD), with particular focus on both ulcerative colitis and Crohn's disease in their moderate to severe forms.
- Novel Therapeutic Agents
- Biosimilar Evaluations
- Disease Remission Studies
Specialized Disease Focus
Shows particular expertise in treating complex IBD manifestations, including fibrostenotic Crohn's disease and investigating bowel urgency in ulcerative colitis patients.
- Transmural Healing Assessment
- Clinical Response Evaluation
- Disease Severity Monitoring
Gastrointestinal Disorders
Extends research into broader gastrointestinal conditions, including gastroparesis, exploring both idiopathic and diabetic manifestations.
- Delayed Gastric Emptying
- Digestive System Disorders
- Therapeutic Innovation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.